<DOC>
	<DOCNO>NCT02831660</DOCNO>
	<brief_summary>The objective collect safety data idarucizumab patient treat dabigatran require rapid reversal anticoagulant effect dabigatran case uncontrolled life-threatening bleeding emergency surgery urgent procedure require .</brief_summary>
	<brief_title>CU Programme Idarucizumab Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Inclusion criterion : Currently take dabigatran etexilate . Age &gt; = 20 year entry . Written Informed consent Group A : Uncontrolled lifethreatening judged physician require reversal agent . Group B : A condition require emergency surgery invasive procedure adequate hemostasis require . Emergency define within follow 8 hour . Exclusion criterion : Contraindications study medication include know hypersensitivity drug excipients ( subject hereditary fructose intolerance may react sorbitol ) . Group A : Patients minor bleeding ( e.g . epistaxis , hematuria ) manage standard supportive care . Patients clinical sign bleed . Group B : surgery procedure elective risk uncontrolled unmanageable bleeding low .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>